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OBJECTIVES To determine if nicotine patches, both as prescribed and used over-the-counter, increase the
risk of first myocardial infarction (MI).
BACKGROUND Although nicotine patches improve smoking cessation rates, case reports have raised the
hypothesis that they may increase the risk of MI.
METHODS A population-based case-control study among 68 hospitals in an eight-county region
surrounding Philadelphia was performed to determine if nicotine patches increase the risk of
first MI. Cases were smokers (current or within the prior year) admitted to all hospitals in the
region with a first MI. Controls were smokers (current or within the prior year) without prior
MI selected from the same region using random-digit dialing. Data were collected by
telephone interviews and chart reviews. The study had 80% power to detect an odds ratio
(OR) of 2.5.
RESULTS A total of 653 cases and 2,990 controls were interviewed. There was no association between
nicotine patches and MI (OR 0.46; 95% CI: 0.09, 1.47), and the confidence interval (CI)
excluded an effect from nicotine patches equal to that from cigarette smoking itself (OR ,
2.5). Among those who abstained from smoking, the OR for use of nicotine patches was 0.25
(95% CI: 0.01, 1.67); among those who smoked concomitantly, the OR for patch use was
0.83 (95% CI: 0.09, 3.81). Adjustment for confounding did not alter the study’s findings (OR
adjusted for confounders that could mask a harmful effect of patches: 0.70; 95% CI: 0.20,
2.46).
CONCLUSIONS Nicotine patches, as used in actual practice, do not appear to be associated with an increased
risk of MI. (J Am Coll Cardiol 2001;37:1297–302) © 2001 by the American College of
Cardiology
Despite the fact that cigarette smoking accounts for more
than 400,000 deaths (1) and billions of dollars of health care
expenditures (2) each year in the U.S., an estimated 48
million Americans continue to smoke (3). Cigarette smok-
ing increases the risk of acute myocardial infarction (MI) by
about two- to fivefold (4), with a greater relative risk among
younger people (5).
Nicotine replacement therapy has been shown to increase
smoking cessation rates, particularly when combined with
counseling (6). However, in 1992, five cases of MI were
reported among nicotine patch users, raising concerns that
nicotine patch use might increase the risk of MI (7). Others
have since reported cases of MI among patch users (8–10).
These reports have fueled the debate over the safety of
nicotine patches (9,11–14) and led to calls both for careful
monitoring and selection of patients who might benefit
from the patch (10,14) and for studies to further investigate
the effects of nicotine patches on MI risk (8). These
concerns have become even more important with the recent
increase in the use of nicotine patches (15).
Data from several recent studies have suggested that
nicotine replacement therapy (nicotine gum or patches)
does not increase the risk for cardiovascular events, even in
people with underlying coronary disease (16–19). These
studies, although valuable, were limited in their ability to
draw conclusions about the risk of MI because their primary
end points were a composite of different clinical events (18),
they had few or no patients with MI (17–19), they were not
designed (17) or sufficiently powered (16,17) to examine
cardiovascular effects, they had high rates of discontinuation
of therapy (17,18) and they examined mostly short-term
nicotine replacement therapy (16,18,19). Equally impor-
tant, controlled trials may not be representative of a more
general population of nicotine replacement users, especially
given the relatively recent introduction of over-the-counter
therapy. Thus, the safety of nicotine patches as they are
currently used by the population has remained unknown.
The specific aim of this study was to examine the effects
of nicotine patches on the risk of first MI.
METHODS
Study site and identification and definition of cases. The
study was conducted in the Philadelphia metropolitan area,
using the population-based Delaware Valley Case-Control
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Network; that is, all 68 acute-care hospitals in an eight-
county region (see Appendix).
Cases were current or recent smokers between the ages of
30 and 65 with a first MI who were hospitalized at one of
the network hospitals from September 1995 through De-
cember 31, 1997. Because smokers may use nicotine re-
placement therapy for an extended period of time after
stopping smoking, some recent smokers may be exposed to
the patch. Therefore, cases were included if they had
smoked cigarettes within one year before their MI (whether
or not they had used a patch). In order to maximize case
identification, hospital-specific systems of case ascertain-
ment were developed and hospitals were contacted on at
least a monthly basis.
Acute MI was defined using the criteria from the Min-
nesota Heart Survey (20). Eighty-four percent of subjects
identified (778 subjects) had their medical records reviewed
for confirmation of their MI. Of the 729 records (94%) with
sufficient information available to verify MI, 85% had MIs
that met the study criteria. Given this high rate of confir-
mation, the 145 subjects for whom charts were not available
are included in the primary study analyses; a separate
analysis excluded these subjects.
Cases were excluded if they 1) had never smoked ciga-
rettes or last smoked cigarettes more than one year before
their MI, 2) had an MI as a complication of a hospitaliza-
tion for a different condition (e.g., postoperatively), 3) had a
history of prior MI, 4) were pregnant or nursing (a relative
contraindication to nicotine patch use), 5) did not have
telephones or did not speak English or 6) did not live in one
of the eight counties of the network.
The participation rate among eligible cases was 68%, and
the charts of 79% of eligible nonparticipants were reviewed
to determine basic demographic characteristics.
Identification and selection of controls. Approximately
four community controls with no history of MI were
selected for each case using a modification of the Waksberg
random-digit dialing method (21). Each randomly derived
telephone number was dialed up to nine times (three
attempts each during the day, evening and weekend) in
order to maximize participation. If there was more than one
eligible person living in a single household, one was chosen
at random. Controls were also smokers (current or recent, as
defined for cases) and met the same exclusion criteria as
cases. The participation rate among known eligible controls
was 51%.
An additional study of nonparticipant controls was con-
ducted over an eight-month period. Two hundred fourteen
consecutive control subjects who refused to participate in
the study were called again, and 85 agreed to answer two
questions (not specified until the subject agreed to partici-
pate) regarding patch use either within the prior day or the
prior week.
Definition of exposure. Because patients with MI may
delay presentation to the hospital (22) and because it is
possible that an effect of nicotine may manifest itself
clinically several days after the patch is discontinued, the a
priori primary definition of exposure to nicotine patches was
any patch use within one week of the index date (the date of
MI for cases and the date of the telephone interview for
controls). Additional analyses considered exposure only if
nicotine patch use occurred one day before the index date.
Data collection. Exposure and covariate data were col-
lected for all subjects by telephone interview. Subjects were
not told of the study hypothesis at any point during the
study.
In order to maximize the validity of nicotine patch
exposure information, cases were interviewed only if they
could be reached within six months of their MI. Controls
also were interviewed only within six months of being
identified in order to prevent selection bias. To further
maximize recall (23,24), all subjects were prompted for
exposure information with indication-specific questions
about smoking cessation, reading of all nicotine patch
names and examination of photographs with pictures of all
available nicotine patches (which all subjects were sent by
mail prior to the interview). One hundred eighty-three
subjects also were reinterviewed to determine reliability of
exposure information, and agreement on patch use was 99%.
Sample size. The study was designed to have 80% power to
detect an odds ratio (OR) for MI among patch users relative
to nonusers of 2.5 (an OR equal to that of smoking itself)
(4), based on an estimated prevalence of patch use in the
control group of 1%, a two-tailed alpha of 0.05, and a
control:case ratio of 4:1 (estimated 691 cases needed).
Because more cases than expected did not meet our criteria
for MI, we had 653 completed cases. However, by recruiting
more controls, we were able to maintain a detectable OR of
2.5.
Analysis. Exact p-values and 95% confidence intervals
(CIs) were calculated for all ORs. Because of the small
number of exposed cases, we first performed exact stratified
analyses for each possible confounder. Confounding was
considered present if the summary OR from the stratified
analyses was at least 10% different from the unadjusted OR
(25). We then performed logistic regression to adjust
simultaneously for those confounders that would mask a
harmful effect of nicotine patches on MI (i.e., those con-
founders that increased the OR in stratified analyses).
The study was approved by the Institutional Review
Boards of all participating hospitals.
Abbreviations and Acronyms
CI 5 confidence interval
MI 5 myocardial infarction
OR 5 odds ratio
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RESULTS
Study population. A total of 653 cases of first MI and
2,990 controls participated in the study. The distribution of
their clinical characteristics is shown in Table 1.
Association between nicotine replacement therapy and
MI. Table 2 presents the association between nicotine
patch use and the risk of MI. There was no statistically
significant association between nicotine patch use and MI
(OR 0.46; 95% CI: 0.09, 1.47). Excluding cases without
medical records to confirm MI did not substantively change
the results (Table 2); the upper limit of the 95% CI still
excluded the a priori OR of 2.5. Including exposure to both
nicotine patch and gum (any nicotine replacement therapy),
the OR was 0.47 (95% CI: 0.15, 1.19). Patch use within the
prior day also was not associated with MI (OR 0.59; 95%
CI: 0.11, 1.98).
Among subjects who smoked any time during the index
week, the use of the patch was not associated with an
increased risk of MI relative to those who smoked but did
not use the patch (OR 0.38; 95% CI: 0.04, 1.54; p 5 0.26).
Comparing those who reported specifically that they
smoked on the same day that they used the patch with those
who smoked cigarettes but did not use the patch, the OR
was 0.83 (95% CI: 0.09, 3.81; p 5 1.0). When comparing
those who used the patch without concurrent smoking with
those who did not use the patch or smoke (i.e., estimating
the effects of using the patch alone without smoking relative
to not smoking and not using the patch), the OR was 0.25
(95% CI: 0.01, 1.67; p 5 0.25).
The effects of adjustment for potential confounders using
exact stratified analysis are shown in Table 3. Five con-
founders actually reduced the OR (i.e., moved it further
away from 1): body mass index, pack-years of smoking,
income, gender and a history of high cholesterol. Adjust-
ment for age, family history, hypertension and insurance
increased the OR by more than 10%. However, for no
analysis did the point estimate of the OR exceed 1.0, nor did
the upper limit of the 95% CI exceed the a priori limit of
2.5. Stratification by the number of the above risk factors
present (0–1, 2, 3, .3) produced an exact OR of 0.35 (95%
CI: 0.04, 1.46; p 5 0.19). Logistic regression adjusting
simultaneously for age, family history, hypertension and
insurance (i.e., all confounders increasing the OR) produced
an OR of 0.70 (95% CI: 0.20, 2.46), again excluding an OR
of 2.5.
Participants versus nonparticipants. Participant cases did
not differ from nonparticipants with respect to age (mean
age 51.1 vs. 51.9, respectively; p 5 0.16) or gender (32% vs.
Table 1. Distribution of Risk Factors Among Cases and Controls*
Cases (n 5 653)
Number With
Factor/Total (%)





Age $50 yrs 391/653 (60%) 713/2,990 (24%) 4.77 (3.97, 5.72)†
Body mass index $25.2 kg/m2‡ 451/650 (69%) 1,480/2,963 (50%) 2.27 (1.89, 2.74)†
Cigarette $19 pack-years‡ 520/637 (82%) 1,457/2,895 (50%) 4.39 (3.53, 5.48)†
Diabetes mellitus 123/643 (19%) 117/2,977 (4%) 5.78 (4.37, 7.64)†
Family history of coronary disease 272/577 (47%) 841/2,740 (31%) 2.01 (1.67, 2.43)†
Female gender 210/652 (32%) 1,721/2,990 (58%) 0.35 (0.29, 0.42)†
Family income ,$30,000/yr 303/612 (49%) 1,273/2,814 (45%) 1.19 (0.99, 1.42)\
History of angina or coronary disease 70/643 (11%) 63/2,960 (2%) 5.62 (3.89, 8.12)†
History of high cholesterol 232/650 (36%) 497/2,981 (17%) 2.77 (2.29, 3.36)†
Hypertension 265/649 (41%) 522/2,981 (17%) 3.25 (2.69, 3.92)†
Private health insurance 530/631 (84%) 2,378/2,838 (84%) 1.02 (0.80, 1.30)\
Race
White 515/650 (76%) 2,266/2,974 (76%) 1.0 (reference)\
Black 108/650 (20%) 603/2,974 (20%) 0.79 (0.62, 0.99)
Other 27/650 (4%) 105/2,974 (4%) 1.06 (0.65, 1.68)
*Numbers may be less than total because subjects reported “don’t know” for risk factors or data missing. †p , 0.001. ‡The
median value in the control group. \p . 0.05.
CI 5 confidence interval; OR 5 odds ratio.
Table 2. Association Between Nicotine Patch Use and Myocardial Infarction: Nicotine Patch











All subjects 3/653 (0.46%) 30/2,990 (1%) 0.46 (0.09, 1.47) 0.26
Only subjects in whom
MI was confirmed
by chart review
3/505 (0.59%) 30/2,990 (1%) 0.59 (0.11, 1.91) 0.55
CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio.
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28% female; p 5 0.21). The only significant difference was
insurance status (p 5 0.006); nonparticipants were more
likely to be on medical assistance (13.1%) than were
participants (5.1%).
Among 142 nonparticipant cases in whom prior medica-
tion data were noted from medical records, no subject had
documented patch use. In contrast, two out of 297 (0.7%)
participant cases had their patch use documented in the
records. Both of these subjects had stated they used the
nicotine patch in the index week during their study inter-
view. No case subject who denied use of the nicotine patch
in the index week had nicotine patch use documented in the
medical record.
Among controls who refused to participate in the study
but agreed to answer questions in the nonparticipation
study, two (2.3%; 95% CI: 0.3%, 8.2%) had used a nicotine
patch within the prior week. This is in comparison with the
1.0% (95% CI: 0.7%, 1.4%) of participant controls who used
the patch within the prior week.
DISCUSSION
Study findings. This large multicenter case-control study
did not detect an increased risk of first MI from nicotine
patches as used by a diverse population in actual practice.
Although the OR of 0.46 is consistent with prior hypoth-
eses that nicotine patches may reduce the risk of cardiovas-
cular events by reducing the amount and intensity of
cigarette smoking (26), the results were not statistically
significant. Therefore, the most important finding was that
the upper limit of the 95% CI of the OR of MI from
nicotine patches (1.47) was lower than the OR of MI from
smoking alone (4,5). Even if nicotine patch users were at
this somewhat increased relative risk of MI during their
short-term use of the patch, this risk would be less than that
of continuing to smoke, which would continue lifelong.
The lack of an association between patch use and MI was
not due simply to the fact that patch users were not
currently smoking; the risk of MI among patch users who
were not smoking was not increased when compared with
those who were not smoking and not using the patch. We
also did not detect an increased risk among patch users who
smoked on the same day as wearing the patch. However, we
had limited power to examine this question, as reflected by
the wide CI.
Comparison with previous studies. These findings add
new evidence to those of previous clinical studies supporting
the safety of nicotine patches (16–19). These prior studies,
however, were not specifically designed or powered to
examine the effect of nicotine patches on MI risk. For
example, a randomized trial of patches did not demonstrate
an increase in a composite cardiovascular event end point
(including congestive heart failure and arrhythmias) among
short-term users of the patch, but was not powered to
examine the effects of patches on MI (18). Most of these
prior studies also were performed under controlled clinical
trial conditions. Our study adds to these studies by demon-
strating no significant increased risk of MI from “real world”
use of the nicotine patch.
The findings of this study also are consistent with several
physiologic and pharmacodynamic properties of nicotine
and nicotine replacement therapy. First, although nicotine
may cause coronary vasoconstriction and worsen myocardial
dysfunction in stunned, ischemic myocardium (26), trans-
dermal nicotine does not appear to increase platelet reactiv-
ity (27) or fibrinogen levels (at least in the short term) (28),
potentially more important determinants of MI risk. Nico-
tine patches also appear to stimulate less catecholamine
release than does cigarette smoking (27). Second, patch
users who abstain from smoking typically have lower nico-
tine levels than those associated with smoking their usual
number of cigarettes (29). Third, even when instructed to
smoke ad libitum, smokers appear to reduce their intensity
of smoke intake while wearing the nicotine patch, suggest-
ing that patch use may reduce consumption of harmful
Table 3. Association Between Nicotine Patch Use and Myocardial Infarction:






None (crude OR) 0.46 (0.09, 1.47) 0.26
Age (,50 versus $50 years) 0.51 (0.10, 1.75) 0.45
Body mass index $25.2 kg/m2 0.40 (0.08, 1.32) 0.18
Cigarette $19 pack-years 0.36 (0.07, 1.18) 0.12
Cigarette smoking in index week 0.46 (0.09, 1.50) 0.25
Diabetes mellitus 0.45 (0.81, 1.50) 0.24
Family history of coronary disease 0.55 (0.11, 1.81) 0.46
Family income ,$30,000 0.32 (0.04, 1.29) 0.15
Gender 0.40 (0.08, 1.32) 0.18
History angina/coronary disease 0.42 (0.08, 1.39) 0.17
History of high cholesterol 0.41 (0.08, 1.35) 0.17
Hypertension 0.52 (0.10, 1.70) 0.34
Private health insurance 0.52 (0.10, 1.69) 0.34
Race (black versus other) 0.45 (0.09, 1.47) 0.25
CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio.
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products other than nicotine in cigarette smoke even if
people continue to smoke while wearing the patch (28,30).
Strengths and potential limitations. This study has sev-
eral important strengths. First, it was population-based,
thus minimizing the risk of selection bias. Second, the study
reflects real-life use of the nicotine patch. Third, and most
important, our study was large enough to exclude a relative
risk from nicotine patches that is smaller than the relative
risk from smoking; that is, it is riskier to continue to smoke
than to use the nicotine patch.
However, several potential limitations of this study must
be considered. First, there were only a few exposed cases.
Although this finding is reassuring, because it reflects the
lack of increased risk from patches, we could not adjust for
all clinical variables simultaneously in multivariable analyses.
Nonetheless, multivariable analysis that simultaneously in-
cluded all variables that increased the OR for patches, the
“worst-case scenario,” found no suggestion of increased risk
from nicotine patches, and the upper 95% CI still excluded
an OR of 2.5.
Second, nonparticipation could have masked an associa-
tion between nicotine patches and MI if nonparticipant
controls were less likely and/or nonparticipant cases were
more likely to use the patch. However, the study of
nonparticipant controls suggested that the prevalence of
patch use might have been higher than that for participants,
and the nonparticipant cases were more likely to be on
medical assistance and thus perhaps less likely to be able to
buy nicotine patches (31). In addition, none of the nonpar-
ticipant cases whose medical records were reviewed had
patch use documented. The potentially higher prevalence of
patch use among nonparticipant controls and lower preva-
lence of patch use among nonparticipant cases suggested by
these analyses would, if anything, have biased our results
toward showing a harmful effect of nicotine patches.
Third, recall bias could have masked an association if
cases were less likely than controls to recall patch use.
However, the use of nicotine patches to stop smoking is a
unique type of drug exposure that is unlikely to be forgotten,
and drug histories were elicited using strategies that have
been shown to improve the response rate to questions about
medication use (23,24). Also, given the media attention
about nicotine patches and MI (7), cases would, if anything,
be more likely to recall patch use preceding their MI. In
addition, chart review of subjects who denied nicotine patch
use did not reveal any documented use of the patch.
Fourth, the study, by design, excluded persons dying of
sudden cardiac death. Therefore, if nicotine patch users
were more likely to suffer sudden death than nonusers, an
association between nicotine patches and MI could have
been masked. However, we are not aware of any data
suggesting an increased risk of sudden death among users of
nicotine replacement therapy. Regardless, for this bias to
mask an OR of 2.5 and produce the OR of 0.46 observed in
this study, nicotine patches would have to be associated with
an almost 10-fold increased risk of sudden cardiac death
(32–34), a risk more than five times that from cigarette
smoking itself (35).
Conclusions. This study did not identify a statistically or
clinically significant association between the use of nicotine
patches and MI in an unselected population. These findings
are consistent with the physiologic and pharmacodynamic
properties of nicotine patches and with other studies that
suggest no serious adverse cardiovascular effects among
patch users. These results add further support to the safety
of nicotine patches when users follow the recommended
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